How to win the cannabis game: The Bioxyne (ASX: BXN) Story

How do you win the cannabis game?

It's a question I've been asking myself for a while.

I've been fascinated by cannabis stocks ever since the glorious bull markets of 2019 and 2020.

The promise was simple: build the infrastructure for a medical market, then capitalise when cannabis goes recreational.

It hasn't quite played out that way.

The word "restructure" is now synonymous with ASX-listed cannabis stocks.

Althea has jettisoned its medical cannabis business entirely. 

Little Green Pharma and Cannatrek are merging. 

The TGA initiated court proceedings against Montu for unlawful advertising.

Epsilon Healthcare was suspended for two years. 

Cann Group has undergone a major debt restructuring.

BOD Science entered administration. 

But there is one company in the space that is not struggling.

Bioxyne (ASX: BXN).

Not just in terms of share price, but in revenue and profit growth.

Bioxyne first secured a GMP manufacturing licence for medical cannabis in Febuary 2024.

It did ~$9 million in revenues from a legacy business and had one employee working on medical cannabis.

This year, it is set to do between $65 and $75 million in revenue. With $16 million in EBITDA on the low end of expectations.

In an industry full of cautionary tales, these numbers are hard to ignore.

The stock has 10-bagged in the last 2 years.

So I flew to Brisbane to visit its facilities and find out: how did Bioxyne win the cannabis game?

Bioxyne (ASX: BXN) is a GMP manufacturer of cannabis products.

It has a large facility about 40 minutes outside of Brisbane, servicing the entire Australian medical cannabis industry.

It does not grow flowers.

It does not own patients.

All it does is pack, label, and manufacture products for the market - cannabis for medical use, as well as MDMA and psilocybin.

To understand where Bioxyne sits in the supply chain, here's a rough breakdown:

The Raw Material Suppliers are the growers, think Cann Group or ECS Botanics. 

These companies grow flower and extract oils.

The challenge with this business model in Australia is that the Canadians have much better margins because they can use 100% of the flower produced.

Nothing is wasted; trimmings go into things like hash and prerolled joints for the recreational market. In Australia, these trimmings are generally destroyed.

The Distributors/Brands are the ones that own the patient relationship, think Montu, Little Green Pharma, Vitura.

While this space can be lucrative, it is very competitive right now - and brands are racing to the bottom on price in order to gain market share.

Vitura, in its recent half-yearly report, said challenges occurred due to “price and margin compression across the competitive medical cannabis sector”.

Bioxyne sits right in the middle. 

Securing raw materials, manufacturing finished products, and delivering them to distributors.

They are the bottleneck of the entire supply chain.

And that's exactly where they want to be.

Some cultivators will have some form of GMP manufacturing capability.

They could pack their own flower and sell directly to distributors, but that’s an extra line item in an already thin-margin business. 

(Also the do it by hand, no economies of scale)

It is much cheaper to outsource. 

When I visited, Bioxyne had a team of three staff members manually inspecting the flower for any issues. 

A service customers paid for, because it was cheaper than doing it themselves.

Having a reliable GMP facility that delivers on time, every time, is everything. 

Distributors spend enormous effort and money getting their products in front of prescribing doctors. 

If the product doesn't show up on time, all of that effort evaporates.

Imagine a patient being prescribed a particular flower, told it'll arrive in two weeks, only for it to take eight.

In the background: a labelling issue, a manufacturing problem, a quality control failure.

The patient doesn't know any of that. They just never choose that product again.

That is a brand killer.

So all of the main distributors and brands (like Little Green Pharma, Cannatrek, Montu) all use Bioxyne for consistency.

Originally, distributors like Montu or Cannatrek would deal directly with cultivators, then pay a company like Bioxyne a fee to handle the GMP side as a contract manufacturer.

Better margins for the distributor, but it came with headaches. 

Flower that didn't show up on time. A product that was out of spec. Quality issues that delayed patients getting their medicine.

Even if this occurred only 10% of the time, the “risk” of losing a patient due to a delayed or cancelled order was too high.

(no pun intended)

Now, distributors put their orders directly through Bioxyne, which manages all cultivator relationships and quality control end-to-end.

This is what's called a white-label model.

The distributors focus on the patient-facing side of the business. 

Bioxyne handles everything else.

Better margins for Bioxyne. Better purchasing power with cultivators. More reliable product for the distributors.

(The ‘one neck to strangle if things go wrong’ policy)

Bioxyne is not the only GMP manufacturer in the market.

But the moat around GMP is significant. 

It takes around two years to get the licence, and it's issued over a specific facility. 

Once a competitor hits the walls of their building, they need a new licence for a new facility.

Bioxyne was smart.

They secured their licence over the entire site, not just the space they currently occupy. Which means they can grow into the surrounding space without having to start from scratch.

Here is how Bioxyne scaled up its facility in 2 years (and still has plenty of room to grow)

(Sorry for the crude, completely not-to-scale drawing)

But the real moat isn't the licence.

It's the reputation.

Jason Hine, Bioxyne's COO, told me a story I haven't been able to stop thinking about.

The $10 haircut.

There's a barber in a small town charging $20 a haircut. Lines out the front. Very popular.

Six months later, someone opens a shop right next door, charging $10.

The lines start to dwindle. Someone asks the original barber: 

"Will you drop your price? You're too expensive."

He put a big sign out the front saying…

"I fix $10 haircuts."

Sure enough, the customers start coming back, unhappy with their cheap haircuts, willing to pay for the service they actually want.

That is Bioxyne's secret.

And I saw it for myself.

While I was there, three staff members were relabelling a product manufactured by a competitor. 

The customer was paying Bioxyne to fix the poor job their previous GMP facility had done.

The staff told me this happens multiple times a week.

Competitors might undercut on price.

They can't compete on reliability.

The tour started out in the original Bioxyne facility.

About 10 clean rooms and an office upstairs.

This was where the company did specialised projects (like flower inspecting), vape mixing, oil manufacturing and MDMA/Psilocibin capsuling and storage.

NEXT, I went to the larger facility.

Lots of staff, Bob Marley music in the background, it was a vibe… and it needs to be for the factory workers.

Three big safes, all monitored with security cameras.

Every single gram of cannabis is accounted for.

What I found interesting was just how much marketing went into the packaging.

In an industry where you can’t advertise, packaging and labelling are the only way to curate the experience.

Glass vs. plastic. Where the sticker goes. The name of the product. The price. And ultimately, the product itself.

Cannabis forums on Reddit are the advertising. 

Consumers rate products publicly, and influencers post reviews. If the product feels cheap, the jar, the label, the unboxing, that IS the experience.

Bioxyne doesn't have a view on any of this.

Glass jar, sticker, bag, custom packaging, they can do it all.

They are the picks and shovels of the industry.

I then went upstairs to see where the magic happens, the cleanrooms where the gummies and cannabis flower are made and packed.

Now, for this next section, I can’t show too many images.

Optimising these processes is effectively the “trade secret” for Bioxyne, and it is what allows them to be more reliable than competitors and to make better margins.

The tour ended with a taste of the Bioxyne-branded gummies (with the cannabis taken out, of course):

For Bioxyne, scale is not the limiting factor. Demand is.

Right now (in Australia), Bioxyne's customers, the distributors, are under pressure. There's been intense regulatory scrutiny on prescription practices, and the environment for distributors is changing.

But there is one tailwind that hasn't fully arrived yet.

Driving laws.

Every Australian state is moving towards changing the rules around driving with cannabis in your system, specifically to not penalise people who are sober but hold a valid prescription.

When Germany changed its equivalent laws, the medical cannabis industry doubled overnight.

In Australia, NSW looks set to be next.

Anecdotally, a friend who switched from street cannabis to medical cannabis told me the driving laws were the single reason he made the switch.

Bioxyne is in the process of building a GMP facility in Scotland, a mirror image of the Brisbane operation, to serve the UK market, which is roughly 4 years behind Australia from a regulatory perspective.

The dominant player in the UK, Curaleaf, is constrained by size. 

Bioxyne has learned from scaling in Brisbane and is building the Scotland facility with room to grow from day one.

The UK also gives Bioxyne a gateway into Europe, a market it is already beginning to service, where countries like Germany are actively looking for best-in-class GMP partners.

Manufacturing in Scotland is expected to begin by the end of 2026. 

This is the big growth piece.

(Bioxyne already supplies a number of Australian companies that are now entering in the UK, giving them a customer launching pad for this new market)

Bioxyne is the only GMP-approved manufacturer of psilocybin and MDMA in Australia (possibly the world).

Batches are small for now, but these products are high-margin.

Right now, Bioxyne supplies these products to clinical trials and authorised prescribers in Australia. 

As this market grows, and I expect it to, Bioxyne will sell the picks and shovels there too.

The biggest risk is simple: the $10 haircut shops get better.

Bioxyne's explosive growth is built on its status as the most reliable operator in the industry. 

If a well-funded competitor closes the quality gap, the margin advantage starts to erode.

The second risk is industry-wide. If demand slows, tighter regulations, changes to prescription practices, or a slowdown in consumer adoption, Bioxyne feels it downstream.

Finally, the regulatory environment cuts both ways. 

Tighter rules are generally good for Bioxyne; they raise the bar for competitors and reinforce the value of best-in-class GMP. 

But if regulations loosen significantly, the way they have in the US and Canada, GMP becomes less of a differentiator.

And one more to watch: if the distributor market consolidates into a monopoly or duopoly, pricing power could shift - think Coles and Woolworths, but for cannabis. 

If that’s the case, Bioxyne may have less pricing power (for example, to pass on increases in energy costs to distributors, as it currently would).

A monopoly or duopoly on the distributor side could be bad for business down the line, and with the Little Green Pharma/Cannatrek merger, it appears the industry is heading in that direction.

Two years ago, Bioxyne’s cannaibs facility had one employee.

Today, it has over 100.

I flew up to Brisbane not knowing what to expect, and left genuinely impressed. 

Somewhere in the supply chain of a messy, complicated, heavily regulated industry… Bioxyne found exactly the right spot to sit.

Every single staff member I spoke to was motivated, engaged, and clearly proud of what they were building.

In an industry that was built by cowboys, Bioxyne feels like the adult in the room.

While the numbers have been very impressive (particularly the growth rate), I think the valuation is being held back by the market's broader sentiment toward cannabis stocks.

Which, let’s be honest, have left many investors burned.  But that's an opportunity.

So, how do you win the cannabis game?

Be the picks and shovels. 

Be the reliable one.

Be the one who fixes $10 haircuts.

As Bixoyne is aspiring to be.

A big thank you to Lerissa, Dr Nick, Mac and of course the COO, Jason Hine, for taking me through the Bioxyne story.

See you all next week, 

The Armchair Analyst

I wrote yesterday that peptides are starting to make their way into the mainstream vernacular… and it doesn’t get much more mainstream than the AFR. 

This is what I woke up to this morning:

It’s a good read. I didn’t know that GLP-1 was short for glucagon-like peptide 1.

The company I’ve invested in to capitalise on this trend is Tetratherix (ASX: TTX), which has developed a nasal spray delivery mechanism for molecules such as peptides.

Paradigm Biopharmaceuticals (ASX: PAR) achieves 50% patient enrolment in its global Phase 3 clinical trial for osteoarthritis pain. Interim results expected in August 2026. (PAR)

🪑 Big catalyst coming up in August for the company -  I’m looking forward to this data.

BCAL Diagnostics (ASX: BDX) submits an application to the Medical Services Advisory Committee for reimbursement of its Pancreatic Cancer blood test under the Australian MBS (Medicare Benefits Scheme). (BDX)

🪑 Reimbursement is one of the key pillars for any diagnostics business. 

This is a very good milestone for BDX to tick off; a positive result here (and subsequent MBS listing) would be a big catalyst for the company. 

Nexsen Limited (ASX: NXN) A$1.2M non-dilutive grant from the Hong Kong government to advance clinical validation and manufacturing of its point-of-care diagnostic product in Asia-Pacific. (NXN)

🪑Nexsen CIO Vipul Bansal is a bit of a guru when it comes to securing non-dilutive grants. A good skill to have. Nice work.

Cleo Diagnostics (ASX: COV) completes collection of 514 blood samples for its pivotal U.S. clinical trial for ovarian cancer diagnostics. (COV)

🪑Just waiting now on a manufacturing partnership agreement before a full timeline on FDA submission and trial results.

Enlitic (ASX: ENL) secures a US$250,000 contract with St. Jude Children’s Research Hospital for data migration services. (ENL)

Optiscan Imaging (ASX: OIL) submits an FDA regulatory dossier for its InSpecta veterinary imaging device for approval in the US. (OIL)

A big overarching update from Cyclopharm (ASX: CYC) on commercialisation activities and expansion of its Technegas lung imaging product in the US. (CYC)

🪑 I really like this update; it's comprehensive and gives existing shareholders a progress update on all the activities the company has undertaken for the US go-to-market strategy. 

How long will it take for this to translate into meaningful revenue? I’m not sure, but at least we can see the momentum is there.

The AFR’s Healthcare Summit is on right now. I enjoyed this read about Health Minister Mark Butler’s comments about the NDIS. (AFR)

Firebrick Pharma (ASX: FRE) secures $1.5M via placement at $0.047 per share. (FRE)

Blackstone raises US$6.3 billion for its next life sciences fund. (Bloomberg)

Tom Brady-backed telehealth AI startup eMed raises US$200M, tops US$2B valuation. (Mobil Health News)

🪑 The continued growth of telehealth companies like eMed, compound pharmacies like Hims and peptides/GLP-1s are all interconnected.

It is the way the healthcare system is moving. More personalised medicine, less about “treating symptoms” and more about “active wellness”.

The future macro thematic is starting to take shape.